[HTML][HTML] Infection risk with immunomodulatory and proteasome inhibitor–based therapies across treatment phases for multiple myeloma: A systematic review and meta …
Background The objective of this review was to determine the impact of immunomodulatory
drugs (IMiDs) and proteasome inhibitor (PI)–based therapy on infection risk in patients with …
drugs (IMiDs) and proteasome inhibitor (PI)–based therapy on infection risk in patients with …
Infection risk with immunomodulatory and proteasome inhibitor–based therapies across treatment phases for multiple myeloma: A systematic review and meta …
BW Teh, SJ Harrison, LJ Worth, KA Thursky… - European Journal of …, 2016 - ejcancer.com
Background The objective of this review was to determine the impact of immunomodulatory
drugs (IMiDs) and proteasome inhibitor (PI)–based therapy on infection risk in patients with …
drugs (IMiDs) and proteasome inhibitor (PI)–based therapy on infection risk in patients with …
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis
BW Teh, SJ Harrison, LJ Worth… - … journal of cancer …, 2016 - pubmed.ncbi.nlm.nih.gov
Background The objective of this review was to determine the impact of immunomodulatory
drugs (IMiDs) and proteasome inhibitor (PI)-based therapy on infection risk in patients with …
drugs (IMiDs) and proteasome inhibitor (PI)-based therapy on infection risk in patients with …
Infection risk with immunomodulatory and proteasome inhibitor–based therapies across treatment phases for multiple myeloma: A systematic review and meta …
BW Teh, SJ Harrison, LJ Worth, KA Thursky… - European Journal of …, 2016 - infona.pl
The objective of this review was to determine the impact of immunomodulatory drugs (IMiDs)
and proteasome inhibitor (PI)–based therapy on infection risk in patients with myeloma …
and proteasome inhibitor (PI)–based therapy on infection risk in patients with myeloma …
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis …
BW Teh, SJ Harrison, LJ Worth, KA Thursky… - European Journal of …, 2016 - europepmc.org
Background The objective of this review was to determine the impact of immunomodulatory
drugs (IMiDs) and proteasome inhibitor (PI)-based therapy on infection risk in patients with …
drugs (IMiDs) and proteasome inhibitor (PI)-based therapy on infection risk in patients with …